Statins and risk of bleeding: An analysis to evaluate possible bias due to prevalent users and healthy user aspects

American Journal of Epidemiology

Volumn 183, Issue 10, 2016, Pages 930-936

  Van Rein, Nienke ^a   Cannegieter, Suzanne C ^a   Le Cessie, Saskia ^a   Rosendaal, Frits R ^a   Reitsma, Pieter H ^a   Van Der Meer, Felix J M ^a   Lijfering, Willem M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

bias (epidemiology); cohort studies; coumarins; hemorrhage; hydroxymethylglutaryl CoA reductase inhibitors

Indexed keywords

ACENOCOUMAROL; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PHENPROCOUMON; ANTICOAGULANT AGENT;

AGE STRUCTURE; ANTICOAGULANT; BLOOD; COHORT ANALYSIS; DISEASE INCIDENCE; ENZYME ACTIVITY; EPIDEMIOLOGY; INHIBITOR; LIFE EXPECTANCY; ORGANIC COMPOUND; RISK ASSESSMENT; STRATIFICATION;

ADULT; AGE; AGED; ANTICOAGULANT THERAPY; ANTIHYPERTENSIVE THERAPY; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; CARDIAC PATIENT; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; INCIDENCE; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NETHERLANDS; PATIENT RISK; PRACTICE GUIDELINE; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; AGE DISTRIBUTION; CHEMICALLY INDUCED; EPIDEMIOLOGY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; STATISTICAL BIAS; VERY ELDERLY;

NETHERLANDS;

AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; BIAS (EPIDEMIOLOGY); COHORT STUDIES; FEMALE; HEMORRHAGE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; NETHERLANDS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS;

EID: 84971539094     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwv255     Document Type: Article

References (25)

1. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very highintensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295(13):1556-1565.
2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383-1389.
3. Wolozin B, Kellman W, Ruosseau P, et al. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol. 2000;57(10):1439-1443.
4. Gao X, Simon KC, Schwarzschild MA, et al. Prospective study of statin use and risk of Parkinson disease. Arch Neurol. 2012; 69(3):380-384.
5. Yang CC, Jick SS, Jick H. Lipid-lowering drugs and the risk of depression and suicidal behavior. Arch Intern Med. 2003; 163(16):1926-1932.
6. García Rodríguez LA, Wallander MA, Tolosa LB, et al. Chronic obstructive pulmonary disease in UK primary care: incidence and risk factors. COPD. 2009;6(5):369-379.
7. Ray JG, Mamdani M, Tsuyuki RT, et al. Use of statins and the subsequent development of deep vein thrombosis. Arch Intern Med. 2001;161(11):1405-1410.
8. Biere-Rafi S, Hutten BA, Squizzato A, et al. Statin treatment and the risk of recurrent pulmonary embolism. Eur Heart J. 2013;34(24):1800-1806.
9. Schlienger RG, Fedson DS, Jick SS, et al. Statins and the risk of pneumonia: a population-based, nested case-control study. Pharmacotherapy. 2007;27(3):325-332.
10. Scranton RE, Young M, Lawler E, et al. Statin use and fracture risk: study of a US veterans population. Arch Intern Med. 2005; 165(17):2007-2012.
11. Rosendaal FR. Statins and venous thrombosis: a story too good to be true? PLoS Med. 2012;9(9):e1001311.
12. Danaei G, Tavakkoli M, Hernán MA. Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-Analysis of statins. Am J Epidemiol. 2012; 175(4):250-262.
13. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158(9): 915-920.
14. van der Laan JR, Thomas S. Summary of cholesterol guideline (first revision) of the Dutch Society of Family Physicians [in Dutch]. Ned Tijdschr Geneeskd. 2000;144(9): 421-427.
15. Bouma M, Rutten GE, de Grauw WJ, et al. Summary of the practice guideline diabetes mellitus type 2 (second revision) from the Dutch College of General Practitioners [in Dutch]. Ned Tijdschr Geneeskd. 2006;150(41):2251-2256.
16. van der Meer FJ, Rosendaal FR, Vandenbroucke JP, et al. Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med. 1993;153(13):1557-1562.
17. Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692-694.
18. You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012; 141(2 suppl):e531S-e575S.
19. Opstelten W, Boode BS, Heeringa J, et al. Summary of the practice guideline atrial fibrillation (first revision) from the Dutch College of General Practitioners [in Dutch]. Ned Tijdschr Geneeskd. 2010;154:A1570.
20. Hernan MA, Robins JM. Confounding. In: Causal Inference. Boston, MA: The President and Fellows of Harvard College 2015 83-94. https://cdn1.sph.harvard.edu/wp-content/uploads/sites/1268/2015/08/hernanrobins-v1.10.30.pdf. Accessed September 1, 2015.
21. Douketis JD, Melo M, Bell CM, et al. Does statin therapy decrease the risk for bleeding in patients who are receiving warfarin? Am J Med. 2007;120(4):369.e9-369.e14.
22. Hernán MA, Alonso A, Logan R, et al. Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology. 2008;19(6):766-779.
23. Vandenbroucke JP. The HRT controversy: observational studies and RCTs fall in line. Lancet. 2009;373(9671): 1233-1235.
24. Szapary L, Horvath B, Marton Z, et al. Short-Term effect of low-dose atorvastatin on haemorrheological parameters, platelet aggregation and endothelial function in patients with cerebrovascular disease and hyperlipidaemia. CNS Drugs. 2004;18(3):165-172.
25. Adams NB, Lutsey PL, Folsom AR, et al. Statin therapy and levels of hemostatic factors in a healthy population: the Multi-Ethnic Study of Atherosclerosis. J Thromb Haemost. 2013;11(6):1078-1084.